Financials Bio-Techne Corporation

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 14:02:28 2025-07-14 EDT			5-day change	1st Jan Change
53.08 ^USD	-1.95%		+3.12%	-26.22%

07:50am	Bio-Techne's Simple Western? Technology Utilized in Recent Fda Approval of Zevaskyn Cell-Based Gene Therapy	CI
07-09	TD Cowen Initiates Bio-Techne at Buy With $65 Price Target	MT

Projected Income Statement: Bio-Techne Corporation

Fiscal Period: June	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	738.7	931	1,106	1,137	1,159	1,218	1,283	1,402
Change	-	26.04%	18.75%	2.81%	1.97%	5.13%	5.29%	9.26%
EBITDA ¹	268.1	385.7	449.3	441	411	425.2	456.8	510.3
Change	-	43.85%	16.5%	-1.85%	-6.81%	3.47%	7.43%	11.71%
EBIT ¹	246.3	362.2	421.3	410.2	370.2	383.6	413.8	467.7
Change	-	47.08%	16.32%	-2.64%	-9.75%	3.63%	7.87%	13.02%
Interest Paid ¹	-19.2	-13.95	-11.31	-11.22	-12.41	-7.399	-9.023	-10.67
Earnings before Tax (EBT) ¹	276.5	148.2	301.4	338.7	185.7	211.5	290.3	350.6
Change	-	-46.41%	103.4%	12.37%	-45.17%	13.92%	37.26%	20.77%
Net income ¹	229.3	140.4	272.1	285.3	168.1	159.5	232.6	281.7
Change	-	-38.76%	93.75%	4.86%	-41.07%	-5.14%	45.85%	21.13%
Announcement Date	8/4/20	8/5/21	8/4/22	8/8/23	8/7/24	-	-	-

¹USD in Million

Estimates

Fiscal Period: June	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3
Net sales ¹	175.8	204.2	224.3	243.6	259	257.7	269.3	290.4	288.2	269.7	271.6	294.1	301.3	276.9	272.6	303.4	306.1	289.5	297	316.2	315	298.8	309.7	338	339.6	323.2	334.3	365.1
Change	-	16.13%	9.82%	8.61%	6.35%	-0.51%	4.48%	7.84%	-0.74%	-6.44%	0.71%	8.31%	2.44%	-8.09%	-1.57%	11.31%	0.88%	-5.44%	2.62%	6.45%	-0.39%	-5.12%	3.63%	9.15%	0.47%	-4.82%	3.43%	9.19%
EBITDA ¹	60.29	83.65	92.69	118.7	105.9	103.7	109.5	121.8	114.3	100.5	104	116.4	120	95.58	93.23	109.3	111.1	95.71	96.11	122.2	110.8	98.18	103.9	127.1	125.1	109.2	114.8	140.5
Change	-	38.74%	10.81%	28.08%	-10.82%	-2.06%	5.64%	11.15%	-6.11%	-12.06%	3.49%	11.87%	3.14%	-20.38%	-2.46%	17.29%	1.57%	-13.82%	0.42%	27.17%	-9.37%	-11.37%	5.84%	22.33%	-1.58%	-12.75%	5.19%	22.37%
EBIT ¹	54.7	78.06	86.83	97.62	99.69	97.35	102.8	114.6	106.6	93.18	96.47	108.7	111.8	86.89	81.94	99.59	101.8	83.23	88.71	110.3	101.3	89.41	95.45	117.6	115.5	97.36	103	129.9
Change	-	42.71%	11.24%	12.42%	2.13%	-2.35%	5.62%	11.42%	-6.99%	-12.56%	3.53%	12.69%	2.88%	-22.31%	-5.69%	21.53%	2.18%	-18.21%	6.58%	24.36%	-8.15%	-11.76%	6.76%	23.25%	-1.86%	-15.68%	5.75%	26.2%
Charge d'intérêts ¹	-4.617	-4.416	-3.585	-2.66	-3.291	-3.409	-2.902	-2.493	-2.505	-3.79	-2.356	-1.367	-3.702	-4.893	-4.329	-4.005	-1.605	-2.176	-2.148	-2.007	-1.45	-1.933	-1.833	-1.833	-1.833	-	-	-
Earnings before Tax (EBT) ¹	61.53	39.34	56.37	45.35	7.113	67.38	86.18	68.77	79.05	103.7	66.43	80.2	88.32	49.56	33.39	61.08	41.66	40.17	42.88	38.27	62.65	-	-	-	-	-	-	-
Change	-	-36.06%	43.29%	-19.54%	-84.32%	847.32%	27.89%	-20.2%	14.95%	31.2%	-35.95%	20.72%	10.13%	-43.89%	-32.63%	82.96%	-31.8%	-3.57%	6.73%	-10.73%	63.69%	-	-	-	-	-	-	-
Net income ¹	58.85	33.4	46.27	45.78	14.96	69.62	80.17	60.74	61.52	89.56	50	70.22	75.48	50.99	27.46	49.06	40.59	33.6	34.89	22.59	52.72	43.35	48.05	66.71	64.4	-	-	-
Change	-	-43.25%	38.57%	-1.06%	-67.32%	365.34%	15.17%	-24.24%	1.29%	45.56%	-44.16%	40.42%	7.5%	-32.45%	-46.14%	78.62%	-17.27%	-17.21%	3.84%	-35.26%	133.42%	-17.78%	10.84%	38.83%	-3.46%	-	-	-
Announcement Date	8/4/20	11/5/20	2/2/21	5/6/21	8/5/21	11/2/21	2/1/22	5/4/22	8/4/22	11/1/22	2/2/23	5/3/23	8/8/23	10/31/23	2/1/24	5/1/24	8/7/24	10/30/24	2/5/25	5/7/25	-	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Bio-Techne Corporation

Fiscal Period: June	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	85.9	110	8.88	146	166	143	-175	-531
Change	-	28.06%	-91.93%	1,544.14%	13.7%	-13.93%	-222.38%	-203.43%
Announcement Date	8/4/20	8/5/21	8/4/22	8/8/23	8/7/24	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Bio-Techne Corporation

Fiscal Period: June	2020	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	51.74	44.3	44.91	38.24	62.88	40.74	47.99	53.74
Change	-	-14.38%	1.37%	-14.84%	64.41%	-35.2%	17.79%	11.97%
Free Cash Flow (FCF) ¹	153.2	307.9	280.4	216.1	236.1	231.6	326.8	724.6
Change	-	100.89%	-8.93%	-22.9%	9.23%	-1.91%	41.08%	121.77%
Announcement Date	8/4/20	8/5/21	8/4/22	8/8/23	8/7/24	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Bio-Techne Corporation

Fiscal Period: June	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	36.3%	41.43%	40.64%	38.8%	35.46%	34.9%	35.61%	36.41%
EBIT Margin (%)	33.34%	38.9%	38.11%	36.09%	31.94%	31.48%	32.26%	33.37%
EBT Margin (%)	37.43%	15.92%	27.26%	29.79%	16.02%	17.36%	22.63%	25.01%
Net margin (%)	31.04%	15.08%	24.61%	25.1%	14.5%	13.09%	18.13%	20.1%
FCF margin (%)	20.75%	33.07%	25.36%	19.02%	20.37%	19.01%	25.47%	51.69%
FCF / Net Income (%)	66.83%	219.26%	103.06%	75.77%	140.45%	145.24%	140.5%	257.22%
Profitability
ROA	9.17%	6.55%	11.94%	13.03%	6.29%	10.13%	10.37%	9.85%
ROE	14.08%	9.51%	16.63%	17.53%	14.11%	13.56%	13.73%	13.75%
Financial Health
Leverage (Debt/EBITDA)	0.32x	0.28x	0.02x	0.33x	0.4x	0.34x	-	-
Debt / Free cash flow	0.56x	0.36x	0.03x	0.67x	0.7x	0.62x	-	-
Capital Intensity
CAPEX / Current Assets (%)	7%	4.76%	4.06%	3.36%	5.42%	3.34%	3.74%	3.83%
CAPEX / EBITDA (%)	19.3%	11.49%	9.99%	8.67%	15.3%	9.58%	10.51%	10.53%
CAPEX / FCF (%)	33.76%	14.39%	16.02%	17.69%	26.63%	17.59%	14.69%	7.42%
Items per share
Cash flow per share ¹	1.302	2.174	1.982	1.572	1.86	1.986	2.43	2.675
Change	-	66.98%	-8.85%	-20.7%	18.32%	6.82%	22.33%	10.09%
Dividend per Share ¹	0.32	0.32	0.32	0.32	0.32	0.32	0.3333	0.32
Change	-	0%	0%	0%	0%	0%	4.17%	-4%
Book Value Per Share ¹	8.764	10.03	10.36	12.14	13.08	12.95	14.58	17.46
Change	-	14.45%	3.34%	17.18%	7.67%	-0.97%	12.6%	19.77%
EPS ¹	1.455	0.8675	1.658	1.76	1.05	0.9629	1.307	1.568
Change	-	-40.38%	91.07%	6.18%	-40.34%	-8.3%	35.71%	20%
Nbr of stocks (in thousands)	152,892	155,567	156,934	157,437	157,585	156,767	156,767	156,767
Announcement Date	8/4/20	8/5/21	8/4/22	8/8/23	8/7/24	-	-	-